Validation of new cancer biomarkers: a position statement from the European group on tumor markers.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Chemistry

• Publication date

  2015-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1373/clinchem.2015.239863PMID 25882892
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Circulating tumor DNA as a liquid biopsy for cancer.

  2015cited by this paper
• Biological and therapeutic impact of intratumor heterogeneity in cancer evolution.

  2015cited by this paper
• Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

  2015cited by this paper
• Translational researchers beware! Unreliable commercial immunoassays (ELISAs) can jeopardize your research

  2014cited by this paper
• FDA Perspective on Companion Diagnostics: An Evolving Paradigm

  2014cited by this paper
• False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125.

  2014cited by this paper
• Registering diagnostic and prognostic trials of tests: is it the right thing to do?

  2014cited by this paper
• Diagnostic clinical genome and exome sequencing.

  2014cited by this paper
• Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union

  2014cited by this paper
• Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer

  2014cited by this paper
• Molecular testing in breast cancer.

  2014cited by this paper
• From biomarkers to medical tests: the changing landscape of test evaluation.

  2014cited by this paper
• Decade in review—clinical trials: Shifting paradigms in cancer clinical trial design

  2014cited by this paper
• Circulating MicroRNAs as a Novel Class of Diagnostic Biomarkers in Gastrointestinal Tumors Detection: A Meta-Analysis Based on 42 Articles

  2014cited by this paper
• A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.

  2014cited by this paper
• Diagnostic clinical genome and exome sequencing.

  2014cited by this paper
• Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.

  2014cited by this paper
• Guidance for laboratories performing molecular pathology for cancer patients

  2014cited by this paper
• Precision treatment for cancer: Role of prognostic and predictive markers

  2014cited by this paper
• Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges

  2013cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers.

  2013cited by this paper
• Trial Designs for Personalizing Cancer Care: A Systematic Review and Classification

  2013cited by this paper
• Evolution of Translational Omics: Lessons Learned and the Path Forward

  2013cited by this paper
• Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications

  2013cited by this paper
• The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

  2013cited by this paper
• Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration

  2013cited by this paper
• Breaking a Vicious Cycle

  2013cited by this paper
• Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.

  2013cited by this paper
• A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study

  2013cited by this paper
• Evaluating many treatments and biomarkers in oncology: a new design.

  2013cited by this paper
• Overview of the use of Oncotype DX® as an additional treatment decision tool in early breast cancer

  2013cited by this paper
• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

  2013cited by this paper
• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

  2013cited by this paper
• Criteria for the use of omics-based predictors in clinical trials

  2013cited by this paper
• Biospecimen reporting for improved study quality (BRISQ).

  2012cited by this paper
• An appeal to medical journal editors: The need for a full description of laboratory methods and specimen handling in clinical study reports

  2012cited by this paper
• Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

  2012cited by this paper
• Publication of tumor marker research results: the necessity for complete and transparent reporting.

  2012cited by this paper
• Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers

  2012cited by this paper
• Multiplicities in cancer research: ubiquitous and necessary evils.

  2012cited by this paper
• Bridging the Gap: Moving Predictive and Prognostic Assays from Research to Clinical Use

  2012cited by this paper
• An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports.

  2012cited by this paper
• Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

  2012cited by this paper
• Biospecimen reporting for improved study quality (BRISQ).

  2011cited by this paper
• A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer

  2011cited by this paper
• Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue.

  2011cited by this paper
• Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens

  2011cited by this paper
• NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

  2011cited by this paper
• QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies

  2011cited by this paper
• The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory

  2011cited by this paper
• Biomarker studies: a call for a comprehensive biomarker study registry

  2011cited by this paper
• Taking a new biomarker into routine use – A perspective from the routine clinical biochemistry laboratory

  2010cited by this paper
• Cancer biomarkers: can we turn recent failures into success?

  2010cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development

  2010cited by this paper
• American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Sources of bias in specimens for research about molecular markers for cancer.

  2010cited by this paper
• Methylated genes as new cancer biomarkers.

  2009cited by this paper
• A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment

  2009cited by this paper
• Use of archived specimens in evaluation of prognostic and predictive biomarkers.

  2009cited by this paper
• Recommended principles and practices for validating clinical molecular pathology tests.

  2009cited by this paper
• The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group

  2009cited by this paper
• MammaPrint™ 70-gene signature: another milestone in personalized medical care for breast cancer patients

  2009cited by this paper
• Using the Principles of Randomized Controlled Trial Design to Guide Test Evaluation

  2009cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE)

  2008cited by this paper
• National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements.

  2008cited by this paper
• Almost all articles on cancer prognostic markers report statistically significant results.

  2007cited by this paper
• The challenges of gene expression microarrays for the study of human cancer.

  2006cited by this paper
• Clinical trial designs for predictive marker validation in cancer treatment trials.

  2005cited by this paper
• REporting recommendations for tumor MARKer prognostic studies (REMARK)

  2005cited by this paper
• Development and validation of therapeutically relevant multi-gene biomarker classifiers.

  2005cited by this paper
• Bias as a threat to the validity of cancer molecular-marker research

  2005cited by this paper
• Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy.

  2003cited by this paper
• Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative.

  2003cited by this paper
• The standards for reporting of diagnostic accuracy.

  2003cited by this paper
• Laser-controlled microdissection of tissues opens a window of new opportunities.

  2003cited by this paper
• The STARD Statement for Reporting Studies of Diagnostic Accuracy: Explanation and Elaboration

  2003cited by this paper
• Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification.

  2003cited by this paper
• Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

  2002cited by this paper
• Phases of biomarker development for early detection of cancer.

  2001cited by this paper
• Uses and abuses of meta-analysis.

  2001cited by this paper
• Breaking the vicious cycle.

  2001cited by this paper
• Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

  2001cited by this paper
• Introduction: strategies to set global quality specifications in laboratory medicine.

  1999cited by this paper
• The uses and abuses of meta-analysis.

  1996cited by this paper
• Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

  1996cited by this paper
• Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

  year unknowncited by this paper

• Systematic Pathway Screening via Integrated Machine Learning Identifies FOXO‐Mediated Transcription Signature for Robust Immunotherapy Response Prediction in Non–Small Cell Lung Cancer

  2026cites this paper
• Evaluating the performance of a resampling approach for internally validating the association between a time-dependent binary indicator and time-to-event outcome

  2025cites this paper
• Biosensors in Cancer Research: A New Frontier in Screening, Diagnosis and Treatment Management

  2025cites this paper
• Electrochemical biosensing in oncology: a review advancements and prospects for cancer diagnosis

  2025cites this paper
• Multi-Cancer Early Detection Tests: State of the Art and Implications for Radiologists.

  2025cites this paper
• Fourier transform InfraRed spectra analyzed by multivariate and machine learning methods in determination spectroscopy marker of prostate cancer in dried serum.

  2024cites this paper
• Neuroendocrine Breast Tumors: Could Multigene Assays Help in Guiding Treatment Decisions? Case Presentation

  2024cites this paper
• Proteomics techniques in protein biomarker discovery

  2024cites this paper
• Biomarkers for Early Cancer Detection: A Landscape View of Recent Advancements, Spotlighting Pancreatic and Liver Cancers

  2024cites this paper
• A preliminary study on the reference intervals of serum tumor marker in apparently healthy elderly population in southwestern China using real-world data

  2024cites this paper
• Correlation between long non-coding RNA MAFG-AS1 and cancer prognosis: a meta-analysis

  2023cites this paper
• Aussagekraft von Prokollagen Typ I aminoterminales Propeptid (P1NP) als Knochenaufbaumarker

  2023cites this paper
• Circulating tumor DNA (ctDNA): can it be used as a pan-cancer early detection test?

  2023cites this paper
• A Phenomic Perspective on Factors In fl uencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Pro fi ling

  2023cites this paper
• Practical application of European biological variation combined with Westgard Sigma Rules in internal quality control

  2022cites this paper
• Neurofilament-Leichtketten (NFL) als prognostischer Biomarker in der Diagnostik der multiplen Sklerose

  2022cites this paper
• Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy

  2022cites this paper
• Going deeper: molecular inflammatory scores in IBD

  2022cites this paper
• Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood

  2022cites this paper
• Pathological Digital Biomarkers: Validation and Application

  2022cites this paper
• Internal Standard Triggered-Parallel Reaction Monitoring Mass Spectrometry Enables Multiplexed Quantification of Candidate Biomarkers in Plasma

  2022cites this paper
• Tumour markers with clinically controlled cut‐offs for suspected cancer

  2021cites this paper
• A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling

  2021cites this paper
• Der Biomarker adrenokortikotropes Hormon (ACTH)

  2021cites this paper
• Methoden klinischer Prüfung in der Onkologie

  2021cites this paper
• Der Biomarker Lipoprotein(a) – Lp(a) in der Diagnostik der peripheren arteriellen Verschlusskrankheit

  2021cites this paper
• The Role of Tumor Markers for Evaluation the Course of Chemotherapy

  2021cites this paper
• A word of caution on using tumor biomarker reference change values to guide medical decisions and the need for alternatives

  2021cites this paper
• Multiplexed triage of candidate biomarkers in plasma using internal standard triggered-parallel reaction monitoring mass spectrometry

  2021cites this paper
• Übersichten : Arbeitsmedizin

  2021cites this paper
• Die Knochenmarker BSP, CTX und NTX und deren Publikationscharakteristika im Rahmen einer bibliometrischen Analyse

  2021cites this paper
• Serum lactate dehydrogenase activities as systems biomarkers for 48 types of human diseases

  2021cites this paper
• MicroRNAs and Extracellular Vesicles as Distinctive Biomarkers of Precocious and Advanced Stages of Breast Cancer Brain Metastases Development

  2021cites this paper
• Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study

  2021cites this paper
• GLIOMAS, TUMORES MALIGNOS QUE SURGEM NO SISTEMA NERVOSO

  2021cites this paper
• Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer

  2021cites this paper
• Der Biomarker TRACP5b (tartratresistente saure Phosphatase 5b)

  2021cites this paper
• Development and Multiple Validation of the Protein Multi-marker Panel for Diagnosis of Pancreatic Cancer

  2021cites this paper
• Simultaneous detection of cluster of differentiation markers on leukemia-derived exosomes by multiplex immuno-polymerase chain reaction via capillary electrophoresis analysis.

  2020cites this paper
• Biomarkers in Lung Cancer.

  2020cites this paper
• Fourier Transform Infrared Spectroscopy as a Cancer Screening and Diagnostic Tool: A Review and Prospects

  2020cites this paper
• Der Tumormarker Thyreoglobulin

  2020cites this paper
• Der Tumormarker Calcitonin

  2020cites this paper
• Tumor markers

  2020cites this paper
• Diagnostic Value of FTIR Spectroscopy, Metabolomic Screening and Molecular Genetics in Saliva for Early Detection of Oral Squamous Cell Carcinoma (OSCC)

  2020cites this paper
• Precision Medicine in Lung Cancer: Challenges and Opportunities in Diagnostic and Therapeutic Purposes

  2020cites this paper
• Der Tumormarker Sialinsäure

  2020cites this paper
• Predictive and Prognostic Markers for Cancer Medicine

  2020cites this paper
• Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology

  2020cites this paper
• Patient-centered Weight Tracking as an Early Cancer Detection Strategy

  2020cites this paper
• High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts

  2020cites this paper
• High FUT3 expression is a marker of lower overall survival of breast cancer patients

  2020cites this paper
• Diagnostic Value of Combinatorial Markers in Colorectal Carcinoma

  2020cites this paper
• Precision medicine

  2020cites this paper
• Biomarkers for Early Cancer Diagnosis: Prospects for Success through the Lens of Tumor Genetics

  2020cites this paper
• Technical Verification and Assessment of Independent Validation of Biomarker Models for Endometriosis

  2019cites this paper
• The Possibility of Systematic Research Fraud Targeting Under-Studied Human Genes: Causes, Consequences, and Potential Solutions

  2019cites this paper
• Der Tumormarker Serotonin

  2019cites this paper
• Extracellular vesicles as cancer liquid biopsies: from discovery, validation, to clinical application.

  2019cites this paper
• Shortcomings in the evaluation of biomarkers in ovarian cancer: a systematic review

  2019cites this paper
• The Progressive Journey from Ductal Carcinoma in situ into Invasive Breast Cancer: An Extensive Systematic Literature Review on Biomarkers

  2019cites this paper
• Der Biomarker 5‑Hydroxyindolessigsäure

  2019cites this paper
• Die Biomarker TSH, TT4, FT4, TT3, FT3 und rT3

  2019cites this paper
• Tumormarker Humanes Choriongonadotropin (HCG) in der Diagnostik von Hodentumoren

  2019cites this paper
• Mass Spectrometry-Based Biomarkers in Drug Development.

  2019cites this paper
• Der Biomarker TSH bei Schilddrüsenautonomien

  2019cites this paper
• Der Tumormarker Prolaktin

  2019cites this paper
• Expressiveness of Bone Markers in Breast Cancer with Bone Metastases

  2019cites this paper
• Sensitive determination of the human epidermal growth factor receptor 2 (HER2) by immuno-polymerase chain reaction with inductively coupled plasma-mass spectrometry detection.

  2019cites this paper
• Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer

  2019cites this paper
• The concentration of the cleaved suPAR forms in pre‐ and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study

  2019cites this paper
• Der Biomarker Cortisol

  2019cites this paper
• Chronic liver disease detection and quantification

  2019cites this paper
• Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?

  2019cites this paper
• Assessment and relevance of the putative DNA/RNA helicase Schlafen-11 in ovarian and breast cancer

  2019cites this paper
• Steroidhormonrezeptoren

  2019cites this paper
• Molekulare Grundlagen der Karzinogenese und molekularbiologische Untersuchungsmethoden

  2019cites this paper
• Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?

  2018cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

  2018cites this paper
• Der Tumormarker Her-2/neu

  2018cites this paper
• Asparaginase‐like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study

  2018cites this paper
• Human Epididymis Protein 4 (HE4)

  2018cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

  2018cites this paper
• Impact of pathological features of brain metastases in prognosis.

  2018cites this paper
• Der Tumormarker HCG in der Diagnostik der Blasenmole

  2018cites this paper
• Der Tumormarker AFP

  2018cites this paper
• Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT

  2018cites this paper
• Biomarker Discovery and Validation in HCC Diagnosis, Prognosis, and Therapy

  2018cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

  2018cites this paper
• Der Tumormarker „neuronenspezifische Enolase“ (NSE)

  2018cites this paper
• Quantitative Proteomics to Support Translational Cancer Research

  2018cites this paper
• A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors

  2018cites this paper
• Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.

  2018cites this paper
• Predictive Value of Epigenetic Signatures

  2018cites this paper
• Bringing 3D tumor models to the clinic – predictive value for personalized medicine

  2017cites this paper
• (Very) Early technology assessment and translation of predictive biomarkers in breast cancer.

  2017cites this paper
• Revisiting biomarker discovery by plasma proteomics

  2017cites this paper
• RNA-based ovarian cancer research from ‘a gene to systems biomedicine’ perspective

  2017cites this paper
• Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer

  2017cites this paper
• Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period

  2017cites this paper